{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:33Z","timestamp":1790916813992,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"\n Introduction<\/jats:title>\n \n Vincristine is limited by its adverse effect of peripheral neuropathy with only a few inconclusive reports of its genetic occurrence. Therefore, the present research work was intended to identify the distribution of rs1045642 polymorphism in\n ABCB1<\/jats:italic>\n gene and rs924607 polymorphism in\n CEP72<\/jats:italic>\n gene, and their association with clinically documented neurological adverse drug reactions to vincristine.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Seventy-five children below 18 years diagnosed with acute lymphoblastic leukemia receiving vincristine were followed for 6 months and analyzed for correlation with vincristine-associated neuropathy.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Twenty of 75 patients were homozygous for the risk allele (TT at rs924607) of\n CEP72<\/jats:italic>\n genotype and 25 of 75 patients were homozygous for the risk allele (TT at rs1045642) of\n ABCB1<\/jats:italic>\n genotype. Among patients with the high-risk\n ABCB1<\/jats:italic>\n genotype (TT at rs1045642), 13 of 25 (52%) developed at least one episode of grade 1\u20133 neuropathy, and had a statistically significant 4.3 times risk of developing neurotoxicity in comparison to patients with the\n ABCB1<\/jats:italic>\n CC or CT genotypes [10 of 50 (20%) patients, odds ratio: 4.3, 95% confidence interval: 1.5\u201312.3;\n P<\/jats:italic>\n = 0.0060]. The patients receiving average dose of vincristine of greater than or equal to 2\u2009mg\/m\n 2<\/jats:sup>\n (58.3%) when compared to those receiving an average dose of less than 2\u2009mg\/m\n 2<\/jats:sup>\n (25.4%) had 4.1 times risk of developing neurotoxicity (odds ratio: 4.1, 95% confidence interval: 1.1\u201314.8;\n P<\/jats:italic>\n = 0.0304).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n This study emphasizes the significant association of\n ABCB1<\/jats:italic>\n genotype (TT at rs1045642) with vincristine-associated neuropathy and highlights the relevance of higher average doses of vincristine in causing neurotoxicity.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000606","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:26:16Z","timestamp":1781454376000},"page":"258-265","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Genetic polymorphisms in ABCB1 and CEP72 genes as pharmacogenetic markers in patients receiving vincristine-based chemotherapy: a preliminary Indian context exploratory study"],"prefix":"10.1097","volume":"36","author":[{"given":"Ramya","family":"Sugumar","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha","family":"M.S.","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jullius","family":"X. Scott","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manickavasagam","family":"M.","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"R2-20261002","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1073\/pnas.90.20.9552","article-title":"Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.","volume":"90","author":"Jordan","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs.","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10428199809057599","article-title":"Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine.","volume":"31","author":"Toh","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"R5-20261002","first-page":"1231","article-title":"Vinca alkaloids.","volume":"4","author":"Moudi","year":"2013","journal-title":"Int J Prev Med"},{"key":"R6-20261002","first-page":"169","article-title":"ABCB1 genetic variants in leukemias: current insights into treatment outcomes.","volume":"10","author":"Ankathil","year":"2017","journal-title":"Pharmacogenomics Pers Med"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00003088-200443090-00001","article-title":"The MDR1 (ABCB1) gene polymorphism and its clinical implications.","volume":"43","author":"Ieiri","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2217\/pgs.14.68","article-title":"Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukaemia.","volume":"15","author":"Ceppi","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2015.0894","article-title":"Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukaemia.","volume":"313","author":"Diouf","year":"2015","journal-title":"JAMA"},{"key":"R10-20261002","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation.","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"R11-20261002","doi-asserted-by":"crossref","first-page":"D1308","DOI":"10.1093\/nar\/gkr798","article-title":"SNPedia: a wiki supporting personal genome annotation, interpretation and analysis.","volume":"40","author":"Cariaso","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"R12-20261002","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/bjc.2014.7","article-title":"Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia.","volume":"110","author":"Lu","year":"2014","journal-title":"Br J Cancer"},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fphar.2016.00238","article-title":"Genetic polymorphisms associated to folate transport as predictors of increased risk for acute lymphoblastic leukaemia in mexican children.","volume":"7","author":"Zaruma-Torres","year":"2016","journal-title":"Front Pharmacol"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.506","article-title":"An inherited genetic variant in cep72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukaemia.","volume":"101","author":"Stock","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R15-20261002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/genes10030191","article-title":"Pharmacogenomic and pharmacotranscriptomic profiling of childhood acute lymphoblastic leukaemia: paving the way to personalized treatment.","volume":"10","author":"Pavlovic","year":"2019","journal-title":"Genes (Basel)"},{"issue":"(13 Suppl)","key":"R17-20261002","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.2527\/jas.2006-449","article-title":"Statistical power calculations.","volume":"85","author":"Lenth","year":"2007","journal-title":"J Anim Sci"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0883073811428379","article-title":"Vincristine related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukaemia.","volume":"27","author":"Brigo","year":"2012","journal-title":"J Child Neurol"},{"key":"R19-20261002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy induced neuropathy.","volume":"13","author":"Windebank","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"R20-20261002","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","article-title":"Ancestry and pharmacogenetics of antileukemic drug toxicity.","volume":"109","author":"Kishi","year":"2007","journal-title":"Blood"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1182\/blood.V128.22.5963.5963","article-title":"Effect of the CEP72 genotype and CYP3A5-mediated metabolism in predicting vincristine-associated peripheral neuropathy.","volume":"128","author":"Agrawal","year":"2016","journal-title":"Blood"},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/tpj.2014.81","article-title":"Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukaemia.","volume":"15","author":"Gregers","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"R23-20261002","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/FPC.0000000000000191","article-title":"Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of paediatric acute lymphoblastic leukaemia treatment in a Spanish population.","volume":"26","author":"Gutierrez-Camino","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cncr.21706","article-title":"Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine.","volume":"106","author":"Hartman","year":"2006","journal-title":"Cancer"},{"key":"R25-20261002","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00280-011-1745-2","article-title":"Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.","volume":"68","author":"Guilhaumou","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"R26-20261002","first-page":"252","article-title":"Risk factors for early-onset peripheral neuropathy caused by vincristine in patients with a first administration of R-CHOP or R-CHOP-like chemotherapy.","volume":"6","author":"Okada","year":"2014","journal-title":"J Clin Med Res"},{"key":"R27-20261002","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/01.WNL.0000154642.45474.28","article-title":"Dose-related vincristine-induced peripheral neuropathy with unexpected off therapy worsening.","volume":"64","author":"Verstappen","year":"2005","journal-title":"Neurology"},{"key":"R28-20261002","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G","article-title":"Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas.","volume":"73","author":"Haim","year":"1994","journal-title":"Cancer"},{"key":"R29-20261002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/jns.12114","article-title":"Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukaemia.","volume":"20","author":"Smith","year":"2015","journal-title":"J Peripher Nerv Syst"},{"key":"R30-20261002","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/pbc.26204","article-title":"Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for paediatric non-CNS cancer.","volume":"64","author":"Gilchrist","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R31-20261002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12098-009-0254-3","article-title":"Vincristine induced neurotoxicity in cancerpatients.","volume":"77","author":"Gomber","year":"2010","journal-title":"Indian J Pediatr"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:00:13Z","timestamp":1790913613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000606","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"2025-12-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}